|
|
Dexcom Inc (NASDAQ: DXCM) |
|
Price: $71.6600
$0.88 
1.243%
|
| Day's High:
| $72.28
| Week Perf:
| 3.51 %
|
| Day's Low: |
$ 70.36 |
30 Day Perf: |
-2.9 % |
| Volume (M): |
2,858 |
52 Wk High: |
$ 132.26 |
| Volume (M$): |
$ 204,797 |
52 Wk Avg: |
$86.00 |
| Open: |
$70.85 |
52 Wk Low: |
$57.52 |
|
|
| Market Capitalization (Millions $) |
29,078 |
| Shares
Outstanding (Millions) |
406 |
| Employees |
9,600 |
| Revenues (TTM) (Millions $) |
4,032 |
| Net Income (TTM) (Millions $) |
576 |
| Cash Flow (TTM) (Millions $) |
40 |
| Capital Exp. (TTM) (Millions $) |
359 |
Dexcom Inc
Company Profile: Dexcom Inc.
Overview:
Dexcom Inc. is a leading medical device company focused on the development and manufacturing of continuous glucose monitoring (CGM) systems tailored for individuals with diabetes. Established in 1999 by Scott Krasner and John Wilson, Dexcom has become a prominent name in diabetes care, offering innovative solutions that enhance the quality of life for people managing the condition.
Product Offerings:
Dexcom's CGM systems consist of a sensor that is inserted beneath the skin to measure glucose levels in the interstitial fluid. These devices are accompanied by transmitters that wirelessly relay real-time glucose data to a receiver or compatible mobile applications, allowing users to monitor their glucose levels continuously. This monitoring capability empowers users to track glucose trends, improving their ability to make informed decisions regarding insulin dosage, dietary choices, and exercise routines.
Key Products:
1. Dexcom G6: The flagship CGM system featuring a smaller sensor, extended wear time, and a no-calibration design. The G6 provides seamless integration with mobile apps, granting users access to real-time glucose readings via their smartphones.
2. Dexcom G5: An earlier version that paved the way for advancements in CGM technology.
3. Dexcom G4 Platinum: A well-established model that has been widely utilized by diabetes patients.
Clinical Accuracy and Approval:
Dexcoms CGM systems are recognized for their high accuracy, achieving a mean absolute difference (MAD) of less than 10% when compared to laboratory reference values. The company's commitment to safety and efficacy is further highlighted by its receipt of various regulatory approvals, including the FDA approval for the Dexcom G6 system in 2018.
Research and Development:
Dexcom prioritizes research and development, continually investing in the exploration of new technologies and features. Collaborations with prominent diabetes advocacy organizations, healthcare professionals, and academic institutions enhance their ability to innovate and improve diabetes management solutions.
Global Presence:
With operations in the United States, Europe, Asia, and Australia, Dexcom has established a robust global footprint. The company is dedicated to building a supportive community around diabetes management, including a dedicated customer support team and an active online community.
Vision:
Dexcoms vision is to empower individuals with diabetes to lead fulfilling lives by streamlining and improving the management of their condition through advanced technology. The company is committed to making diabetes care more accurate, accessible, and convenient, ultimately enhancing the independence and well-being of its users.
Company Address: 6340 Sequence Drive San Diego 92121 CA
Company Phone Number: 200-0200 Stock Exchange / Ticker: NASDAQ DXCM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Wed, Mar 19 2025 10:12 AM UTC
The Future of Type 2 Diabetes Management: Embracing Technology Over MedicationIn a gr...
|
| Business Update
Published Tue, Jan 7 2025 4:11 PM UTC
Dexcom Poised to Share Strategic Insights at J.P. Morgan Healthcare Conference In January 2025, the global leader in continuous glucose monitoring, Dexcom, Inc. (NASDAQ: DXCM), is set to partake in the 43rd annual J.P. Morgan Healthcare Conference one of the most influential gatherings in the health sector. Scheduled for January 13th at noon EST, the presentation promises to...
|
| Business Update
Published Tue, Nov 19 2024 2:47 PM UTC
Dexcom and Oura Join Forces to Revolutionize Metabolic Health MonitoringIn a significant advancement for health technology, DexCom, Inc. (NASDAQ: DXCM), recognized as the global leader in glucose biosensing, and Oura, the innovative company behind the world-renowned smart ring, announced a strategic partnership aimed at enhancing metabolic health for millions. This collabor...
|
| Dexcom Inc
DexCom Inc. Reports Strong Q3 Earnings Amid Legal Challenges; Investors Weigh Future PerformancenSAN DIEGO, CA ? October 24, 2024n ? DexCom, Inc. (NASDAQ: DXCM) has reported a notable increase in third-quarter earnings for 2024, characterized by a double-digit income advance fueled by moderate revenue improvement. The diabetes management firm stated that net income surged by 17.24% to $0.34 per share, reflecting a robust performance amid ongoing market turbulence. Revenue grew slightly by 2.001%, reaching $993.8 million compared to the same period last year.In contrast, the company faced challenges compared to its second quarter, with revenue showing a decline of -0.986% from $1.00 billion, and income per share down -2.86% from $0.35 per share. Additionally, sales in the United States segment fell by ?1.64%, although growth in key international and distributor segments helped mitigate some of the losses. The distributor segment rose by 0.43%, while the direct and international segments saw impressive gains of 11.53% and 11.82%, respectively.
|
| Announcement
Published Mon, Oct 14 2024 5:25 PM UTC
DexCom Faces Class Action Lawsuit: Investors Urged to Act Before October 21, 2024 DeadlineIn recent developments concerning DexCom, Inc. (NASDAQ: DXCM), a class action securities lawsuit has been filed against the diabetes management company, drawing the attention of investors and stakeholders alike. The legal firm Levi & Korsinsky, LLP, has issued a notification regarding ...
|
| Per Share |
Current |
| Earnings (TTM) |
1.44 $ |
| Revenues (TTM) |
9.94 $
|
| Cash Flow (TTM) |
0.1 $ |
| Cash |
1.49 $
|
| Book Value |
5.18 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.44 $
|
| Revenues (TTM) |
9.94 $ |
| Cash Flow (TTM) |
0.1 $ |
| Cash |
1.49 $
|
| Book Value |
5.18 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Distributor |
|
 84.86 % |
of total Revenue |
| Direct |
|
15.18 % |
of total Revenue |
| United States |
|
70.63 % |
of total Revenue |
| International |
|
29.41 % |
of total Revenue |
|
|
4.35%